1. The GENESIS Trial: 6-Month Results A Randomized, Multi-center Study of the Pimecrolimus-Eluting and Paclitaxel-ElutinG Coronary Stent System in PatiENts with De Novo LEsionS of the Native Coronary ArterIeS Stefan Verheye, MD, PhD, FESC Antwerp Cardiovascular Institute Middelheim, Antwerp, Belgium SCAI / ACCi2 2008 S Verheye, K Dawkins, J Dens, W Rutsch, D Carrie, J Schofer, C Lotan, C Dubois, SA Cohen, A Lansky, Genesis Investigators

2. Nothing to disclose Disclosures

3. Drug-Eluting Stents Remaining Challenges ChallengeOpportunity Complex patient subsets still present a challenge Optimized delivery of new or combination of active compounds Acute and sub-acute stent thrombosis may be more frequent than with bare stents New agents addressing different physiologic pathways Delayed stent thrombosis, a previously unknown condition is a real and present danger Different class of polymers Complete drug elution or less hypersensitivity inducing active agents Coated Stents Have Inherent Limitations: - Poor control over release kinetics - Limited universe of deliverable drugs - Prone to peeling and sticking - Drug and polymer ‘entombed’ on stent ‘Broad Spectrum’ delivery capability Different type of stents and polymers Overlapping Stents: - Over dosing at overlap site - Over dosing at overlap site - Dose dump at overlap site - Dose dump at overlap site - Polymer contact erosion - Polymer contact erosion - Polymer flaking - Polymer flaking Different class of polymers or no polymers ‘Gentler’ class of active agents

4. Conor CoStar ™ Stent 180 Day Porcine Model A second generation polymer technology A second generation polymer technology –Conor uses a bioresorbable polymer with minimal contact with the vessel wall, the result is reduced polymer tissue interaction and no long term residual drug or polymer A second generation polymer technology A second generation polymer technology –Conor uses a bioresorbable polymer with minimal contact with the vessel wall, the result is reduced polymer tissue interaction and no long term residual drug or polymer

5. Conor Reservoir Technology A unique platform for drug delivery A unique platform for drug delivery –The reservoir system in the Conor Stent design provides the ability to load drug and control the delivery time and rate A unique platform for drug delivery A unique platform for drug delivery –The reservoir system in the Conor Stent design provides the ability to load drug and control the delivery time and rate

6. Conor SymBio ™ Dual Drug Stent Paclitaxel Pimecrolimus Multiple Independent, Controlled Drug Release from Adjacent Reservoirs

7. Pimecrolimus Inhibits the Inflammatory Response Pimecrolimus Blocks inflammatory response Prevents IL-2/3/4 and TNF α release release DNA Prevents NFAT mediated transcription of cytokines Prevents dephosphorylation of NFAT Pimecrolimus-FKBP- 12 complex binds and deactivates calcineurin Pimecrolimus binds to FKBP-12 TCR Stimulus X X X X X

8. Paclitaxel Inhibits Smooth Muscle Cell Proliferation CellCycle G2M G1 S Prophase Metaphase Anaphase Telophase Paclitaxel binds to microtubules to prevent mitosis X X Inhibits smooth muscle cell proliferation Inhibits neointimal hyperplasia Prevents restenosis

9. Paclitaxel and Pimecrolimus Dual Drug Components Adapted from: Atherosclerosis 1996;123:17-31 This drug combination targets two separate aspects of the restenosis process Pimecrolimus Paclitaxel Post Injury 180 days0 days

10. The Conor Drug Choice Next generation ‘gentler’ drug –Pimecrolimus is conducive to endothelial salvage –Pimecrolimus has a broad therapeutic window –Pimecrolimus’ diffusion characteristics may better penetrate into the microvascular areas of atherosclerotic plaque –Pimecrolimus potency may provide a more broad cytokine inhibition effect

11. In Vitro Release Kinetics for Pimecrolimus and Paclitaxel Studies

12. Potential Corio/SymBio Advantages Pimecrolimus acts to prevent restenosis without delaying vessel healing Pimecrolimus acts to prevent restenosis without delaying vessel healing Dual Drug Delivery is designed as a stronger solution to fight restenosis Dual Drug Delivery is designed as a stronger solution to fight restenosis A Stent platform designed for better control of drug delivery with no residual drug and a reduced risk of long-term adverse events A Stent platform designed for better control of drug delivery with no residual drug and a reduced risk of long-term adverse events

13. Single De Novo Native Coronary Artery Lesions Reference Vessel Diameters: 2.5 - 3.5 mm Lesion Length: <25 mm Sites in UK, Belgium, France, Germany and Israel Corio™ Pimecrolimus-Eluting Stent (325µg) N = 150 patients Primary Endpoint: 6-Month In-Stent Late Loss Sub-Studies; 6-Month IVUS (first 30 pts. for each arm) Dual antiplatelet therapy for 6 months GENESIS Trial Prospective, Three-arm, Asymmetric Randomization (1:2:2) CoStar ® Paclitaxel-Eluting Stent (10µg) N = 75 patients SymBio™ Pimecrolimus/Paclitaxel- Eluting Stent (162.5µg/10µg) N = 150 patients Clinical/MACE Angiographic/IVUS 1-Yr.2-Yr.3-Yr.4-Yr.5-Yr. 30- Day 6-Mo.

14. Safety and Efficacy Endpoints Primary Endpoint Non-inferiority of in-stent late loss at six months Non-inferiority of in-stent late loss at six months –Dual pimecrolimus/paclitaxel compared to CoStar ® –Pimecrolimus compared to CoStar ® Secondary Endpoints Device, lesion and procedural success Device, lesion and procedural success Major Adverse Cardiac Event (MACE) Major Adverse Cardiac Event (MACE) –30 day, 6 month, 1 through 5 year follow-up In-segment late loss In-segment late loss In-stent and in-segment MLD and binary restenosis In-stent and in-segment MLD and binary restenosis % Volume Obstruction % Volume Obstruction Late acquired stent malapposition Late acquired stent malapposition

15. Trial Suspended Enrollment in the GENESIS Trial was suspended on April 28 th, 2007, before full enrollment was completed This decision was made by the study PIs in consultation with Conor Medsystems The decision was made to analyze the data available on all enrolled patients at the time of trial suspension

16. Patient Demographics CoStar ® (N = 49) SymBio™ (N = 97) Corio™ (N = 100) Age Age 64.4 ± 9.6 (49) 59.9 ± 10.1 (97) 64.1 ± 10.0 (100) Gender (% Male) Gender (% Male) 71.4% (35/49) 78.4% (76/97) 80.0% (80/100) Prior MI Prior MI 22.5% (11/49) 29.9% (29/97) 26.0% (26/100) Prior PCI Prior PCI 26.5% (13/49) 28.9% (28/97) 33.0% (33/100) Prior CABG Prior CABG 6.1% (3/49) 0.0% (0/97) 2.0% (2/100) Diabetes Mellitus Diabetes Mellitus 36.7% (18/49) 17.5% (17/97) 32.0% (32/100) Insulin Dependent Insulin Dependent 16.7% (3/18) 11.8% (2/17) 46.9% (15/32) Unstable Angina Unstable Angina 24.4% (10/41) 42.0% (34/81) 28.7% (25/87) Ejection Fraction (%) Ejection Fraction (%) 61.8 ± 8.9 (47) 63.7 ± 12.5 (87) 63.7 ± 12.1 (97)

17. Lesion Characteristics CoStar ® (N = 49) SymBio™ (N = 101) Corio™ (N = 100) Target Vessel Target Vessel LAD LAD40.8%51.5%49.0% Circumflex Circumflex24.5%17.8%24.0% RCA RCA34.7%30.7%27.0% Lesion Length (mm) Lesion Length (mm) 14.42  5.98 13.75  5.42 14.93  5.49 Eccentric Eccentric14.3%33.7%31.0% Bifurcation Lesion Bifurcation Lesion20.4%27.7%28.3% Angulation > 45° Angulation > 45°10.2%7.9%6.0% Thrombus Thrombus0.0%1.0%0.0% Calcification (mod/sev) Calcification (mod/sev)32.7%20.8%34.0% TIMI 0 – 1 Flow TIMI 0 – 1 Flow2.0%0.0%1.0%

18. QCA Analysis CoStar ® (N = 49) SymBio™ (N = 97) Corio™ (N = 100) Pre-procedure QCA Measures Pre-procedure QCA Measures RVD (mm) RVD (mm) 2.81  0.47 (49) 2.87  0.50 (101) 2.79  0.45 (99) MLD (mm) MLD (mm) 0.72  0.31 (49) 0.78  0.37 (101) 0.76  0.38 (99) % DS (%) % DS (%) 73.86  10.78 (49) 72.41  12.57 (101) 72.91  12.09 (99) Post-procedure QCA Measures Post-procedure QCA Measures RVD (mm) RVD (mm) 2.84  0.47 (49) 2.92  0.51 (100) 2.82  0.42 (100) In-lesion MLD (mm) In-lesion MLD (mm) 2.41  0.49 (49) 2.41  0.45 (100) 2.33  0.47 (100) In-stent MLD (mm) In-stent MLD (mm) 2.82  0.42 (49) 2.83  0.39 (98) 2.81  0.38 (99) In-lesion % DS (%) In-lesion % DS (%) 15.50  7.41 (49) 17.43  7.98 (100) 17.67  11.67 (100) In-stent % DS (%) In-stent % DS (%) 5.41  6.22 (49) 7.43  5.74 (98) 6.15  4.75 (99) Acute Gain, In-lesion (mm) Acute Gain, In-lesion (mm) 1.69  0.52 (49) 1.63  0.52 (100) 1.57  0.50 (99) Acute Gain, In-stent (mm) Acute Gain, In-stent (mm) 2.10  0.49 (49) 2.05  0.46 (98) 2.04  0.43 (98)

19. Late Loss at 6 Months 0.42  0.48 1.07  0.59 0.69  0.58 0.58  0.58 1.40  0.67 0.96  0.73 Primary Endpoint Difference 0.82  0.12 Difference 0.38  0.13

20. MLD (mm)Diameter Stenosis (%)Restenosis (%) 2° Angiographic Endpoints CoStarCorio SymBio

21. Pattern of Restenosis Focal Gap Stent Margin Focal Body Diffuse In-stent Diffuse Proliferative Total Occlusion

22. IVUS Follow-up at 6 Months 27.1  12.4 16.6  12.0 41.2  11.5

23. MACE at 30 Days CoStar ® (N = 49) SymBio™ (N = 97) Corio™ (N = 100) MACE MACE0.0%0.0%6.0% Cardiac Death Cardiac Death0.0%0.0%0.0% Myocardial Myocardial Infarction Infarction0.0%0.0%6.0% Q-Wave MI Q-Wave MI0.0%0.0%2.0% Non Q-Wave MI Non Q-Wave MI0.0%0.0%4.0% TVR TVR0.0%0.0%1.0%

24. MACE at 6 Months Overall MACE p<0.0001 (Both Treatment Arms Compared with Control)

25. Stent Thrombosis

26. Conclusions Despite pre-clinical data suggesting marked efficacy of pimecrolimus in suppressing neointimal hyperplasia, the extent of tissue growth and resulting rates of TVR at 6 months were highest in patients treated with the Corio™ Pimecrolimus-Eluting Stent These rates were reduced by nearly 2/3 by co-elution of full-dose paclitaxel with ½ dose pimecrolimus in the SymBio™ Pimecrolimus/Paclitaxel Eluting Coronary Stent Suppression of neointimal hyperplasia was maximal with paclitaxel alone Despite pre-clinical data suggesting marked efficacy of pimecrolimus in suppressing neointimal hyperplasia, the extent of tissue growth and resulting rates of TVR at 6 months were highest in patients treated with the Corio™ Pimecrolimus-Eluting Stent These rates were reduced by nearly 2/3 by co-elution of full-dose paclitaxel with ½ dose pimecrolimus in the SymBio™ Pimecrolimus/Paclitaxel Eluting Coronary Stent Suppression of neointimal hyperplasia was maximal with paclitaxel alone

27. Conclusions The GENESIS trial is the first trial to use Conor reservoir technology to enable dual drug delivery for the treatment of de novo coronary lesions The trial demonstrates the ability to deliver two drugs independently with each drug having an affect on the tissue response to coronary intervention The GENESIS trial is the first trial to use Conor reservoir technology to enable dual drug delivery for the treatment of de novo coronary lesions The trial demonstrates the ability to deliver two drugs independently with each drug having an affect on the tissue response to coronary intervention

28. 1. Pimecrolimus, as a cytokine inhibitor is not efficacious in the prevention of restenosis in humans Take home messages 2.The reservoir platform shows safety and feasibility in delivering 2 different drugs with different release kinetics 3.Based on the unique and advantageous properties of the platform, new programs and larger scale clinical programs are being developed, i.e. Conor- Sirolimus (RES-ELUTION)

29. Back up slides

30. Procedural Success CoStar ® (N = 49) SymBio™ (N = 97) Corio™ (N = 100) Device Success Device Success98.0%97.9%92.0% Lesion Success Lesion Success100.0%100.0%98.0% Procedure Success Procedure Success100.0%100.0%94.0%

31. Comparison of Neointimal Volume Among Previous Drug-Eluting Stent Trials GENESIS Trial 9-m 8-m6-m9-m

32. Incomplete Stent Apposition (ISA) Baseline Persistent Resolved Late Acquired ISA 14 (26.4%) 8 6 0 (0%) Serial IVUS Analysis (n=53 cases)

33. Stent Overlap Analysis CoStar ® SymBio™Corio™ Post-procedure Stent Overlap QCA Post-procedure Stent Overlap QCA No. of Stent Overlap No. of Stent Overlap288 Stent Overlap Length (mm) Stent Overlap Length (mm) 4.06  1.62 2.84  1.34 3.05  2.14 Overlap MLD (mm) Overlap MLD (mm) 2.92  0.29 2.88  0.38 3.06  0.30 Overlap % DS (%) Overlap % DS (%) -3.98  5.63 -0.54  7.50 -1.06  5.70 6-Month F/U Overlap QCA 6-Month F/U Overlap QCA Overlap MLD (mm) Overlap MLD (mm) 2.38  0.29 2.33  0.63 1.34  0.96 Overlap % DS (%) Overlap % DS (%) 9.27  14.22 10.71  20.28 42.41  39.56 Overlap Restenosis (%) Overlap Restenosis (%)0.0%0.0%37.5% Overlap Late Loss (mm) Overlap Late Loss (mm) 0.54  0.58 0.55  0.63 1.72  0.81

34. GENESIS Trial: CEC Adjudicated MI Site/ Patient ID Days to Event Treatment Assignment CEC Adjudicated EventNarrative 502-0060CorioNQMI Periprocedural MI associated with index revascularization 512-0110CorioNQMI Periprocedural MI associated with index revascularization 518-01062CorioNQMI Periprocedural MI associated with TVR 522-0120CorioNQMI Periprocedural MI associated with index revascularization 523-0070CorioQMI Periprocedural MI associated with index revascularization 523-01556CorioNQMIPeriprocedural MI associated with TVR

35. Late Loss at 6 Months Compared With CoStar II at 9 Months 0.42 1.07 0.69 0.58 1.40 0.96 0.49 0.64 6-mo.9-mo.6-mo.9-mo.

36. Stent Thrombosis Compared With CoStar II

37. Statistical Analysis Primary Analytical Subset Intent-to-treatIntent-to-treat –Consists of all patients randomized where attempt to treat with study device was made. Patients will be analyzed in the treatment group to which they were randomized Secondary Analytical Subset Intent-to-treat and per protocolIntent-to-treat and per protocol –All diabetic patient outcomes –Pre-dilatation versus direct stenting technique –All patients with overlapping stents –Long lesions (> 20 mm) –Small vessels (2.5 mm RVD)